NEW YORK (MarketWatch) - Pfizer Inc. and Kohlberg Kravis Roberts & Co. LP Said Monday That year affiliate of KKR Would pay $ 2.4 billion in cash to buy Pfizer's Capsugel unit, Described As The world leader in hard capsules and innovator year in drug-delivery systems.
In 2010, Capsugel Recorded $ 750 Million in Revenue and More Than 180 Manufactured one billion hard capsules.
"We share Capsugel oD's for icts future potential to grow, Develop and Deliver year continues to unmatched quality of products," Said Henry Kravis, co-chief executive of private-equity powerhouse KKR, in a statement.
Separately, Pfizer Said icts new-drug application for tafamidis Received a Refusal-to-file letter from The Food and Drug Administration make quick cash.
The company, part of the Dow Jones Industrial Average, Said The federal agency Determined That its applications for a novel, oral investigational compound for patients with Familial Amyloid Polyneuropathy Transthyretin With Was Not sufficiently complete to permit substantive review.
The New York-based pharmaceutical company Said It's Working with the FDA to resubmit The application as Quickly As Possible.
"The Company Believes thats the Additional Information Needed to support this filing est disponible Without Further clinical studies," Pfizer said.
